News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,785 Results
Type
Article (16105)
Company Profile (105)
Press Release (270567)
Multimedia
Podcasts (74)
Webinars (13)
Section
Business (91571)
Career Advice (481)
Deals (16379)
Drug Delivery (78)
Drug Development (39078)
Employer Resources (54)
FDA (6782)
Job Trends (6679)
News (157537)
Policy (14966)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (502)
Accelerated approval (14)
Adcomms (11)
Allergies (69)
Alliances (24275)
ALS (58)
Alzheimer's disease (513)
Antibody-drug conjugate (ADC) (157)
Approvals (6976)
Artificial intelligence (218)
Autoimmune disease (45)
Automation (12)
Bankruptcy (166)
Best Places to Work (4704)
BIOSECURE Act (9)
Biosimilars (121)
Biotechnology (40)
Bladder cancer (49)
Brain cancer (31)
Breast cancer (247)
Cancer (1605)
Cardiovascular disease (178)
Career advice (433)
Career pathing (15)
CAR-T (55)
CDC (7)
Cell therapy (172)
Cervical cancer (9)
Clinical research (33886)
Collaboration (764)
Compensation (334)
Complete response letters (35)
COVID-19 (1115)
CRISPR (46)
C-suite (450)
Cystic fibrosis (59)
Data (1997)
Decentralized trials (1)
Denatured (19)
Depression (46)
Diabetes (135)
Diagnostics (1476)
Digital health (8)
Diversity (3)
Diversity, equity & inclusion (15)
Drug discovery (123)
Drug pricing (137)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (34745)
Editorial (24)
Employer branding (8)
Employer resources (50)
Events (40628)
Executive appointments (552)
FDA (7947)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (500)
Gene editing (77)
Generative AI (19)
Gene therapy (185)
GLP-1 (491)
Government (1627)
Grass and pollen (4)
Guidances (172)
Healthcare (3985)
HIV (11)
Huntington's disease (9)
IgA nephropathy (39)
Immunology and inflammation (84)
Immuno-oncology (18)
Indications (53)
Infectious disease (1194)
Inflammatory bowel disease (76)
Inflation Reduction Act (10)
Influenza (30)
Intellectual property (117)
Interviews (61)
IPO (6336)
IRA (41)
Job creations (2184)
Job search strategy (388)
JPM (29)
Kidney cancer (10)
Labor market (29)
Layoffs (225)
Leadership (9)
Legal (3670)
Liver cancer (30)
Longevity (8)
Lung cancer (260)
Lymphoma (149)
Machine learning (16)
Management (18)
Manufacturing (432)
MASH (68)
Medical device (1481)
Medtech (1488)
Mergers & acquisitions (10504)
Metabolic disorders (467)
Multiple sclerosis (55)
NASH (14)
Neurodegenerative disease (86)
Neuropsychiatric disorders (38)
Neuroscience (944)
Neurotech (1)
NextGen: Class of 2026 (1706)
Non-profit (667)
Now hiring (17)
Obesity (248)
Opinion (158)
Ovarian cancer (44)
Pain (113)
Pancreatic cancer (68)
Parkinson's disease (82)
Partnered (11)
Patents (226)
Patient recruitment (121)
Peanut (12)
People (30630)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8864)
Phase 2 (14238)
Phase 3 (13024)
Pipeline (2051)
Policy (153)
Postmarket research (1502)
Preclinical (3509)
Press Release (27)
Prostate cancer (91)
Psychedelics (17)
Radiopharmaceuticals (147)
Rare diseases (366)
Real estate (2751)
Recruiting (20)
Regulatory (11511)
Reports (15)
Research institute (638)
Resumes & cover letters (58)
Rett syndrome (5)
RNA editing (6)
RSV (27)
Schizophrenia (73)
Series A (93)
Series B (55)
Service/supplier (2)
Sickle cell disease (48)
Special edition (11)
Spinal muscular atrophy (83)
Sponsored (10)
Startups (1777)
State (2)
Stomach cancer (10)
Supply chain (56)
Tariffs (75)
The Weekly (53)
Vaccines (317)
Venture capital (32)
Weight loss (164)
Women's health (28)
Worklife (4)
Date
Today (5)
Last 7 days (191)
Last 30 days (807)
Last 365 days (11199)
2026 (1016)
2025 (11480)
2024 (13368)
2023 (15056)
2022 (20686)
2021 (21408)
2020 (20199)
2019 (15694)
2018 (12332)
2017 (14468)
2016 (13735)
2015 (16166)
2014 (12971)
2013 (10957)
2012 (11760)
2011 (12298)
2010 (11235)
Location
Africa (341)
Alabama (19)
Alaska (1)
Arizona (80)
Arkansas (3)
Asia (21695)
Australia (2778)
California (3368)
Canada (1519)
China (600)
Colorado (147)
Connecticut (145)
Delaware (159)
Europe (43499)
Florida (633)
Georgia (85)
Hawaii (1)
Idaho (10)
Illinois (364)
India (44)
Indiana (245)
Iowa (2)
Japan (289)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (6)
Maryland (452)
Massachusetts (2735)
Michigan (53)
Minnesota (177)
Mississippi (1)
Missouri (34)
Montana (8)
Nebraska (8)
Nevada (16)
New Hampshire (8)
New Jersey (1513)
New Mexico (7)
New York (946)
North Carolina (630)
North Dakota (2)
Northern California (1537)
Ohio (88)
Oklahoma (5)
Oregon (19)
Pennsylvania (744)
Puerto Rico (12)
Rhode Island (17)
South America (527)
South Carolina (10)
Southern California (1467)
Tennessee (54)
Texas (503)
United States (13459)
Utah (63)
Virginia (163)
Washington D.C. (47)
Washington State (236)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
286,785 Results for "astrazeneca pharmaceuticals lp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.
January 30, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
December 22, 2025
·
1 min read
·
Annalee Armstrong
CAR-T
AstraZeneca Pays $630M for Complete Global Rights Over AbelZeta’s CAR T
The arrangement will boost AstraZeneca’s cell therapy portfolio as the pharma targets $80 billion in revenue by 2030.
January 20, 2026
·
2 min read
·
Tristan Manalac
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
January 14, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
AstraZeneca Makes Another AI Deal With $555M Algen Alliance
AstraZeneca has invested heavily in AI, primarily through collaborations, including an up to $5.3 billion partnership with China’s CSPC Pharmaceutical in June.
October 6, 2025
·
2 min read
·
Tristan Manalac
Earnings
AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat.
November 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AstraZeneca begins trading on the New York Stock Exchange
February 2, 2026
·
2 min read
Press Releases
Lantern Pharma’s LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
January 20, 2026
·
9 min read
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
AstraZeneca in January also stopped its $610 million plans to construct a vaccine R&D and manufacturing site in the U.K.
September 15, 2025
·
2 min read
·
Tristan Manalac
1 of 28,679
Next
